Leaders Forge Ahead in 2026: J.P. Morgan's Business Leaders Outlook and the Biotech Future

Subheadline: Cautious macro sentiment, resilient company confidence, and AI-driven strategy shape the year ahead for the life sciences.

Executive Summary

The 2026 J.P. Morgan Business Leaders Outlook, published on January 7, 2026, finds that sentiment among midsize business leaders has shifted from uncertainty to proactive planning. National economic optimism rebounded to 39% after a midyear low of 32%, while 71% of respondents remain optimistic about their own company's performance. For biotechnology and life sciences companies, the survey offers a useful snapshot of the operating environment: revenue and profit expectations remain positive, workforce expansion continues, and artificial intelligence is becoming embedded in business and R&D processes. At the same time, tariff pressures and a cautious global outlook create headwinds.

Introduction

After a fluctuating 2025, business leaders in the United States are entering 2026 with a more stable—though guarded—economic outlook. The latest annual Business Leaders Outlook from J.P. Morgan Commercial Banking captures this stabilization. The survey also includes an Innovation Economy segment made up of early-stage startups and venture-backed, high-growth companies, making the findings especially relevant to biotechnology, digital health, and emerging medical technology ventures.

For the biotechnology industry, macroeconomic sentiment is only part of the picture. Company-level confidence remains elevated, and innovation-driven businesses continue to prioritize growth, talent, and efficiency. This article examines the survey's key findings and their implications for biotech leaders, investors, researchers, and healthcare stakeholders.

Survey Context and Evidence Base

The Business Leaders Outlook is an annual survey conducted by J.P. Morgan Commercial Banking among midsize business leaders. It tracks sentiment on the global, national, and local economies, along with company performance expectations, workforce plans, technology adoption, and policy concerns. The 2026 report was published on January 7, 2026, and includes responses from leaders across industries; a separate Innovation Economy analysis focuses on early-stage, venture-backed, and high-growth companies.

Because the survey is based on executives' perceptions, it should be viewed as a sentiment indicator rather than a direct measure of scientific or clinical progress. However, it offers evidence-based context for how companies are planning capital deployment, hiring, and technology investment in the year ahead.

Research Findings

National Economic Optimism Recovers from Midyear Low

The survey found that 39% of business leaders are optimistic about the national economy for 2026. This is a rebound from the midyear 2025 low of 32%, but remains well below the 65% recorded at the start of 2025. The decline from the prior year reflects the impact of tariffs, policy changes, and market volatility.

Company-Level Confidence Remains Strong

Despite macro uncertainty, 71% of business leaders are optimistic about their own company's performance in 2026. This suggests that many companies believe they can manage through economic turbulence with internal strategy, operational improvements, and targeted investment.

Global and Local Outlooks Diverge

Optimism about the global economy stands at 28%, with 50% neutral and 23% pessimistic. Local and regional economic optimism declined from 59% to 44%, indicating that leaders are attuned to localized challenges even as global conditions remain subdued.

Revenue and Profit Expectations

Roughly three-quarters (73%) of respondents expect revenue growth in 2026, and 64% project higher profits. Nearly half (48%) plan to expand their workforce, pointing to continued investment in human capital.

AI Adoption and Workforce Impact

Artificial intelligence is increasingly influential in workforce planning. Twenty-seven percent of leaders anticipate some headcount impact from AI in 2026. The most common AI applications include process automation (62%), predictive analytics (44%), and market intelligence (42%). For biotechnology, these categories align closely with bioinformatics, AI-driven drug discovery, and clinical trial optimization.

Tariffs as a Cost Pressure

Sixty-one percent of respondents report that tariffs have had a negative effect on their costs, while 30% say they have not been affected. This is a significant concern for companies that rely on global supply chains, including biomanufacturers and research organizations.

Innovation Economy Sentiment

Respondents from Innovation Economy companies report higher optimism: 66% are optimistic about their industry, and 82% about their company's performance. However, 33% expect a recession or believe the economy is already in one. This divergence points to confident individual strategies against a backdrop of macroeconomic caution.

Industry Impact

For the biotechnology industry, the survey suggests several important trends.

First, company-level confidence is a strong indicator that R&D pipelines, clinical development programs, and commercialization plans remain intact. Biotech firms often operate with longer time horizons and multiple financing stages; even in a cautious economic environment, executives with strong clinical data and clear regulatory pathways are likely to continue investing.

Second, AI adoption is no longer experimental. The survey's finding that process automation, predictive analytics, and market intelligence are the most common AI uses mirrors the growing role of machine learning in target identification, biomarker discovery, and manufacturing optimization. Biotech companies that integrate AI effectively may gain cost advantages and faster cycle times.

Third, workforce expansion plans of 48% suggest continued demand for scientific talent, clinical researchers, regulatory specialists, and data scientists. Yet the 27% of leaders expecting AI-related headcount impact signals that some routine tasks may be automated, allowing staff to focus on higher-value research and development.

Fourth, tariff exposure is a tangible risk for biomanufacturing and supply chains. Reagents, instruments, raw materials, and finished pharmaceuticals may all be affected. Companies may need to diversify suppliers, build regional manufacturing capacity, or reassess sourcing strategies.

Finally, the Innovation Economy segment—which includes many life sciences startups—shows high optimism at the company level, suggesting that venture-backed therapeutic and diagnostics companies remain active. However, the elevated recession expectations among this group may influence financing rounds, partnership discussions, and speed-to-milestone planning.

Clinical and Regulatory Perspective

The Business Leaders Outlook is not a clinical study, but its findings have regulatory and clinical relevance. As biotech companies plan for 2026, they will be making decisions about which programs to advance into clinical trials, how to allocate resources across therapeutic areas, and whether to invest in digital endpoints or decentralized trial infrastructure.

Regulatory considerations remain central to commercialization. FDA and EMA decisions, along with evolving frameworks for AI-enabled medical devices and software, will shape market access. The survey's emphasis on AI adoption suggests that companies are increasingly using computational tools in research, but regulatory acceptance depends on validation, transparency, and real-world evidence.

Additionally, tariff-related cost increases could influence the affordability of medicines and diagnostic products. Companies will need to weigh supply chain resilience against pricing pressures. From a clinical perspective, no therapeutic or diagnostic claims should be drawn from the survey; it is a business sentiment report, not an assessment of medical outcomes.

Future Outlook

Looking ahead to the next 5–15 years, the trends identified in the 2026 Business Leaders Outlook are likely to deepen. Artificial intelligence will move deeper into every stage of biotechnology—from target discovery and protein engineering to clinical trial design and post-market surveillance. The survey's current findings on process automation and predictive analytics are early indicators of a broader transformation.

Precision medicine, genomics, gene editing, and biomanufacturing will remain central growth areas. The company-level optimism reported by leaders suggests sustained commitment to these fields, even as macroeconomic conditions fluctuate. However, investment will likely become more selective, with capital flowing toward programs that demonstrate strong scientific differentiation, clear regulatory pathways, and realistic reimbursement potential.

Tariffs and trade policy will continue to affect global supply chains. Biomanufacturers may invest in regionalized production and digital supply chain monitoring to mitigate risk. In parallel, collaboration among industry, academic medical centers, and regulatory agencies will be essential to maintain innovation ecosystems.

Over the longer term, the biotechnology industry's ability to convert scientific discovery into patient impact will depend on financial resilience, data infrastructure, and talent development. The 2026 outlook suggests that leaders are preparing to do exactly that.

Key Takeaways

• 39% of business leaders are optimistic about the U.S. national economy in 2026, recovering from 32% at midyear but down from 65% a year ago.
• 71% remain optimistic about their own company's performance, and 73% expect revenue growth.
• AI adoption is widespread, with 62% using process automation, 44% predictive analytics, and 42% market intelligence.
• 61% report negative cost impacts from tariffs.
• Innovation Economy companies—including many life sciences startups—show high company optimism (82%) but also higher recession expectations (33%).
• For biotech, the outlook underscores resilience in R&D investment, the growing role of AI in research and operations, and the need for supply chain agility.

Sources

• J.P. Morgan. "2026 Business Leaders Outlook: Expectations & Trends." January 7, 2026. https://www.jpmorgan.com/insights/markets-and-economy/business-leaders-outlook/2026-us-business-leaders-outlook